Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Austinites gathered at The Pitch for the Breakthrough Type 1 Diabetes Walk to raise awareness and funding for advocacy and research into Type 1 diabetes.

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Other strategic highlights: Insulet launched U.S. full market release of the Omnipod 5 App for iPhone and was named No. 1 insulin pump for new pump users in Europe. For the year ending Dec. 31, 2024, ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.